Sarepta's Worst Week: A Black Box, 500 Pink Slips, and a Gene Therapy Identity Crisis
Sarepta slapped the FDA's most serious safety warning on its Duchenne gene therapy while cutting 500 jobs in a single week. With Elevidys revenue down 75% from its peak and fatal liver cases in the rearview mirror, the gene therapy poster child is in full survival mode.
The Double Punch Nobody Wanted
Imagine launching a breakthrough gene therapy for kids with a devastating muscle disease, watching sales soar past $800 million in a single year, and then having to slap the most serious safety warning in medicine on the label while firing a quarter of your workforce. That's Sarepta Therapeutics right now.
The company just added a black box warning to Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD), a progressive disease that robs boys of their ability to walk. At the same time, Sarepta announced it's cutting roughly 500 jobs as part of a sweeping corporate restructuring. Two pieces of terrible news, delivered together like a Band-Aid ripped off both knees.
A black box warning is the FDA's equivalent of a flashing neon sign that says "serious danger ahead." It's the harshest safety label the agency can require, and it sits in a literal black-bordered box at the top of a drug's prescribing information. Doctors notice it. Insurers notice it. Patients' families notice it.
What's in the Box
The warning centers on acute serious liver injury and acute liver failure, including fatal cases. In plain English: Elevidys can cause a patient's liver to shut down, sometimes within weeks of a single infusion.
The trouble typically starts within eight weeks after treatment, showing up as spikes in liver enzymes (the blood markers doctors use to gauge liver health). Patients with preexisting liver problems or chronic liver disease face higher risk. The FDA now requires liver function testing before infusion and weekly monitoring for the first three months afterward, along with steroids to try to keep the immune system from overreacting.
But liver toxicity isn't the only concern on the label. Elevidys also carries warnings for immune-mediated myositis (muscle inflammation triggered by the immune system), myocarditis (inflammation of the heart), and infusion-related allergic reactions that can be severe enough to cause anaphylaxis. Certain patients with specific gene deletions involving exons 8 and 9 appear especially vulnerable to the muscle inflammation, which tends to hit about a month after treatment.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The darkest chapter in Elevidys's safety story came in 2025, when the FDA reported two fatal cases of acute liver failure in non-ambulatory pediatric boys who received the therapy. Those deaths led regulators to narrow the label so that only ambulatory DMD patients aged four and older (kids who can still walk) are eligible.
A Revenue Rollercoaster
The financial arc of Elevidys tells its own story. After gaining initial FDA approval in June 2023 and an expanded label in June 2024, the drug looked like a commercial rocket ship. Q4 2024 alone brought in $384 million in net product revenue. Full-year 2024 sales hit $821 million.
Then gravity kicked in. Safety concerns, regulatory restrictions, and lower demand started dragging numbers down. By Q2 2026, Elevidys revenue had cratered to just $98 million for the quarter. That's a roughly 75% drop from the Q4 2024 peak. It's like watching a restaurant go from a two-hour wait to empty tables in a matter of months.
Why 500 People Are Cleaning Out Their Desks
The layoffs aren't just a cost-cutting exercise; they're a full corporate strategy reset. Sarepta says the restructuring should save approximately $400 million annually, with about $120 million coming from personnel cuts and another $300 million from slashing spending on deprioritized pipeline programs.
The company is pivoting its R&D focus toward what it calls "high-impact programs," with particular emphasis on its siRNA (small interfering RNA) platform. Think of it as Sarepta hedging its bets: instead of going all-in on gene therapy, it's diversifying into a different technology that uses small molecules to silence disease-causing genes.
Management framed the restructuring as necessary for maintaining financial flexibility, especially with 2027 financial obligations looming. Translation: the company needs to make sure it has enough cash to keep the lights on and service its debt while Elevidys revenue stays under pressure.
A Warning Sign for the Whole Neighborhood
Sarepta's problems don't exist in a vacuum. Elevidys uses an AAV (adeno-associated virus) vector to deliver a functional gene into patients' cells, and liver toxicity has become a recurring theme across the entire AAV gene therapy category.
Zolgensma, Novartis's gene therapy for spinal muscular atrophy, already carries its own black box warning for serious liver injury, including fatal cases. Hemgenix, the hemophilia B gene therapy, doesn't have a boxed warning but still requires weekly liver monitoring for three months. The pattern is hard to ignore: when you flood the body with viral vectors, the liver often takes the hit.
Analysts are reading Sarepta's troubles as a cautionary tale for the broader sector. Regulators have clearly grown more willing to impose harsh safety restrictions after serious liver events. The gene therapy dream isn't dead, but the market may be shifting toward tighter patient selection, more intensive monitoring, and a longer road to proving these treatments are worth the risk.
Wall Street Isn't Feeling Generous
The analyst reaction has been cautious to bearish. The most common concern is straightforward: a black box warning and narrowed label mean fewer eligible patients, which means less revenue. Add in higher compliance costs and weakened confidence in Sarepta's platform, and the bear case writes itself.
Bulls point out that Elevidys is still the only approved gene therapy for DMD, which gives it a monopoly of sorts. And Sarepta presented new data at the World Muscle Society Congress in 2026 showing meaningful functional benefit in older ambulatory patients, suggesting the evidence base is still growing.
But monopolies don't mean much if doctors are scared to prescribe your product. The combination of safety signals, revenue decline, and workforce cuts paints a picture of a company in transition, not a company on offense.
The Bigger Question
Sarepta's situation forces an uncomfortable conversation about gene therapy's fundamental promise. These are supposed to be one-and-done treatments: a single infusion that fixes a genetic disease for life. The pitch is extraordinary. But when a single dose can also cause fatal liver failure, the calculus gets painfully complicated, especially when your patients are children.
The company isn't giving up. Newer data presentations suggest Sarepta is still building the clinical narrative around Elevidys. The pivot toward siRNA technology also signals that management sees a future beyond AAV gene therapy.
But for the 500 employees heading home with cardboard boxes, and for the families of DMD patients weighing an agonizing risk-benefit decision, the future feels a lot less certain than it did a year ago. Sarepta bet big on gene therapy. The question now is whether the house still stands.
Clinical & Regulatory
4 min read
The $3.95 Million Drug That Costs More Than Most Houses
Ultragenyx just priced its new gene therapy Fayuvi at $3.95 million per patient, making it the second most expensive drug in the world. It's a one-time treatment for a fatal childhood brain disease with zero alternatives, and it's reigniting the fiercest debate in biotech: who pays for a genetic cure?
